Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
Gottlieb AB, McInnes IB, Rahman P, Kollmeier AP, Xu XL, Jiang Y, Sheng S, Shawi M, Chakravarty SD, Lavie F, Mease PJ. Gottlieb AB, et al. Among authors: chakravarty sd. RMD Open. 2023 Feb;9(1):e002789. doi: 10.1136/rmdopen-2022-002789. RMD Open. 2023. PMID: 36828643 Free PMC article. Clinical Trial.
Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry.
Kavanaugh A, Papp K, Gottlieb AB, de Jong EMGJ, Chakravarty SD, Kafka S, Langholff W, Farahi K, Srivastava B, Scher JU. Kavanaugh A, et al. Among authors: chakravarty sd. BMC Rheumatol. 2018 Sep 29;2:29. doi: 10.1186/s41927-018-0034-7. eCollection 2018. BMC Rheumatol. 2018. PMID: 30886979 Free PMC article.
Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
Mease P, Husni ME, Kafka S, Chakravarty SD, Harrison DD, Lo KH, Xu S, Hsia EC, Kavanaugh A. Mease P, et al. Among authors: chakravarty sd. Arthritis Res Ther. 2020 Mar 6;22(1):43. doi: 10.1186/s13075-020-2126-1. Arthritis Res Ther. 2020. PMID: 32143685 Free PMC article. Clinical Trial.
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.
Helliwell PS, Gladman DD, Chakravarty SD, Kafka S, Karyekar CS, You Y, Campbell K, Sweet K, Kavanaugh A, Gensler LS. Helliwell PS, et al. Among authors: chakravarty sd. RMD Open. 2020 Feb;6(1):e001149. doi: 10.1136/rmdopen-2019-001149. RMD Open. 2020. PMID: 32209721 Free PMC article. Clinical Trial.
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Chakravarty SD, Xu XL, Subramanian RA, Agarwal P, Sheng S, Jiang Y, Zhou B, Zhuang Y, van der Heijde D, Mease PJ. McInnes IB, et al. Among authors: chakravarty sd. Arthritis Rheumatol. 2021 Apr;73(4):604-616. doi: 10.1002/art.41553. Epub 2021 Mar 17. Arthritis Rheumatol. 2021. PMID: 33043600 Free PMC article. Clinical Trial.
Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study.
Mease P, Elaine Husni M, Chakravarty SD, Kafka S, Parenti D, Kim L, Hung Lo K, Hsia EC, Kavanaugh A. Mease P, et al. Among authors: chakravarty sd. ACR Open Rheumatol. 2020 Nov;2(11):640-647. doi: 10.1002/acr2.11180. Epub 2020 Oct 19. ACR Open Rheumatol. 2020. PMID: 33073933 Free PMC article.
69 results